| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $2,279,783 ) |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA288613 | Advancing Thyroid Cancer Diagnostics with AI-enhanced Multimodal Optical Histopathology | 000 | 2 | NIH | 2/2/2026 | $439,250 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01NS140292 | DeepStroke+: An Advanced Mobile AI Diagnostic Tool for Fast and Precise Detection of Acute Strokes in Mobile Stroke Units, Emergency Rooms, and Telestroke Triage | 000 | 2 | NIH | 1/19/2026 | $534,966 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01HL177797 | Role of Cdk9 in the Pathogenesis of Pulmonary Fibrosis | 000 | 2 | NIH | 2/12/2026 | $654,870 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01DK134340 | A randomized, sham-controlled clinical trial evaluating individualized neuromodulation of cortical regions involved in neurogenic overactive bladder in Multiple Sclerosis | 000 | 4 | NIH | 12/17/2025 | $338,159 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | U01CA268813 | A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC) | 000 | 4 | NIH | 1/16/2026 | $305,910 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA285209 | Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors | 000 | 3 | NIH | 1/12/2026 | $440,870 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA280746 | Targeting phenethyl isothiocyanate to mitochondria in lung carcinogenesis | 000 | 3 | NIH | 1/27/2026 | $592,923 |
| | 2026 | 2026 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA269835 | Mechanisms of STING in malignant progression and therapy of CLL. | 000 | 4 | NIH | 2/11/2026 | $442,928 |
| | 2026 | 2025 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01NS121405 | S100A4 mediated immune suppression in GBM | 000 | 5 | NIH | 12/11/2025 | $0 |
| | 2026 | 2025 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01EY026156 | The Impact of Sleep on Network Coding and Perceptual Performance | 000 | 9 | NIH | 11/25/2025 | $0 |
| | 2026 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01EB035545 | Artificial intelligence-integrated mechanistic modeling for rational design of nanoparticles to improve organ targeting and safety | 000 | 2 | NIH | 12/5/2025 | -$418,254 |
| | 2026 | 2025 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA253865 | Nanoparticle delivery of miRNA-based therapeutics to overcome clinical challenges in triple negative breast cancer | 000 | 5 | NIH | 12/31/2025 | $0 |
| | 2026 | 2025 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01AG077685 | Central and peripheral immune cross-talk in Alzheimer's disease and their modulation by a novel immunotherapy | 000 | 3 | NIH | 10/21/2025 | $0 |
| | 2026 | 2024 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | U01CA244107 | Biophysical roles of pre-metastatic niche evolution on transport of circulating tumor cells | 000 | 5 | NIH | 1/29/2026 | $0 |
| | 2026 | 2024 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R56AG085576 | Multi-omic integrative analysis of shared and distinct inflammation networks across neurodegenerative disorders | 000 | 1 | NIH | 1/2/2026 | $0 |
| | 2026 | 2024 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R37CA251318 | P38 MAPK is a molecular switch that controls the acquired resistance in adoptive cell therapy | 000 | 6 | NIH | 11/20/2025 | -$77,934 |
| | 2026 | 2024 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R21NS127229 | Patterned optogenetic neuromodulation to reprogram glioma stem cells | 000 | 1 | NIH | 2/6/2026 | $0 |
| | 2026 | 2024 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01NS118584 | Age-related TDP-43 neuropathology: using disease-driving mechanisms to guide classification | 000 | 2 | NIH | 10/1/2025 | -$941,155 |
| | 2026 | 2024 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA271682 | Validation of a novel 3D culture platform for TNBC treatment selection | 000 | 3 | NIH | 1/16/2026 | $0 |
| | 2026 | 2024 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA244344 | Novel Targeted Therapeutics for Breast Cancer | 000 | 5 | NIH | 12/2/2025 | -$6,025 |
| | 2026 | 2023 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA239255 | Role of tumor microenvironment-derived cholesterol in CD8+ T-cell exhaustion | 000 | 5 | NIH | 12/8/2025 | -$10,691 |
| | 2026 | 2023 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA232433 | Chemoprevention of lung cancer by targeting lonidamine to mitochondria | 000 | 5 | NIH | 1/12/2026 | $0 |
| | 2026 | 2023 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA222959 | Mechanism of Intratumoral Transport of Particulate Drugs | 000 | 5 | NIH | 1/14/2026 | $0 |
| | 2026 | 2022 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R21NS125509 | Methods and devices to assist and improve cerebrospinal fluid drainage | 000 | 1 | NIH | 11/25/2025 | $0 |
| | 2026 | 2022 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA222064 | Hes1-loss promotes dysregulation of epithelial homeostasis and inflammation in a serrated adenocarcinoma model | 000 | 6 | NIH | 1/10/2026 | -$1 |
| | 2026 | 2021 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01DE027251 | Learning-Based Approach for Personalized Craniomaxillofacial Surgical Planning | 000 | 5 | NIH | 11/21/2025 | -$16,032 |
| | 2026 | 2021 | THE METHODIST HOSPITAL RESEARCH INSTITUTE | 6565 FANNIN ST STE D200 | HOUSTON | TX | 77030-2703 | HARRIS | USA | R01CA208703 | Modulation of tumor inflammatory factor for immune therapy | 000 | 5 | NIH | 1/12/2026 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $50,646,779 ) (Continued on the next page) |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01EY026156 | The Impact of Sleep on Network Coding and Perceptual Performance | 000 | 9 | NIH | 1/8/2025 | $475,319 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA163910 | Targeting ER stress response in B-cell chronic lymphocytic leukemia | 000 | 12 | NIH | 1/22/2025 | $403,750 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01DE021863 | Outcome-Driven Approach to Minimize the Risks of Facial Distortion Following CMF Surgery | 000 | 10 | NIH | 7/7/2025 | $623,140 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA288403 | Decoupling acute toxicities and antitumor efficacy in adoptive cell therapy | 001 | 2 | NIH | 5/26/2025 | $59,380 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA288613 | Advancing Thyroid Cancer Diagnostics with AI-enhanced Multimodal Optical Histopathology | 000 | 1 | NIH | 12/25/2024 | $593,383 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01HL177797 | Role of Cdk9 in the Pathogenesis of Pulmonary Fibrosis | 000 | 1 | NIH | 12/31/2024 | $705,334 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01HL177797 | Role of Cdk9 in the Pathogenesis of Pulmonary Fibrosis | 001 | 1 | NIH | 2/25/2025 | $0 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01DK134340 | A randomized, sham-controlled clinical trial evaluating individualized neuromodulation of cortical regions involved in neurogenic overactive bladder in Multiple Sclerosis | 000 | 3 | NIH | 12/18/2024 | $305,092 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01DK137111 | Transforming Curiosity into Donation: Validating a Risk Prediction Index to Detect and Prevent Drop-Out in Potential Living Kidney Donors who are Racial/Ethnic Minorities | 000 | 3 | NIH | 8/1/2025 | $239,256 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01NS119587 | Harnessing Neuroplasticity of Postural Sensorimotor Networks Using Non-Invasive Spinal Neuromodulation to Maximize Functional Recovery After Spinal Cord Injury | 000 | 4 | NIH | 8/15/2025 | $632,816 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01MH127979 | Targeting the HIV-1 Reservoir in Myeloid Cells | 001 | 5 | NIH | 9/23/2025 | $72,546 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA258477 | The Unique Roles of Tumor-Specific Th9 Cells for Solid Tumor Eradication | 001 | 5 | NIH | 5/22/2025 | $39,674 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01CA258477 | The Unique Roles of Tumor-Specific Th9 Cells for Solid Tumor Eradication | 000 | 5 | NIH | 2/14/2025 | $357,063 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01AI080779 | Modulation of innate immune cells to create transplant tolerance | 000 | 13 | NIH | 4/23/2025 | $484,500 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R21CA292295 | Development of new Pt-based ROS storm inducing polymers with tumor specific toxicity | 000 | 1 | NIH | 8/20/2025 | $403,485 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | K76AG088424 | Virtual Reality-Based Cognitive Stimulation Games for Enhancing Attention and Preventing Delirium in Older Surgical Patients with Cognitive Impairment: A Randomized Controlled Pilot Trial | 000 | 1 | NIH | 9/2/2025 | $242,840 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R24AI194877 | Center for the Dissemination of Ultra-Long-Acting Antiretroviral Release Technology: DART Resource Program | 000 | 1 | NIH | 8/20/2025 | $846,258 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R56AI192360 | LDHA-dependent T-cell effector programs in heart transplantation | 000 | 1 | NIH | 8/7/2025 | $300,000 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R21AI187979 | Development of a stable mRNA prophylactic vaccine against SARS-CoV-2 omicron variant | 000 | 1 | NIH | 8/18/2025 | $161,500 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01AG077685 | Central and peripheral immune cross-talk in Alzheimer's disease and their modulation by a novel immunotherapy | 001 | 3 | NIH | 8/12/2025 | $52,639 |
| | 2025 | 2025 | METHODIST HOSPITAL, THE | 6670 BERTNER AVE | HOUSTON | TX | 77030-2602 | HARRIS | USA | R01AG077685 | Central and peripheral immune cross-talk in Alzheimer's disease and their modulation by a novel immunotherapy | 000 | 3 | NIH | 2/14/2025 | $592,201 |
|
